Insulet Faces Securities Fraud Class Action Over Omnipod Safety

The legal action, titled Hu v. Insulet Corporation et al. (No. 26-cv-13062), follows significant stock volatility linked to voluntary medical device corrections. Investors claim Insulet misrepresented the reliability of its Omnipod 5, DASH, and Eros platforms, which were found to have internal tubing tears. These defects caused insulin to leak inside the devices rather than reaching patients, leading to potential under-delivery of medication.

Market reaction to these disclosures was swift. On March 12, 2026, the share price fell 6.88% after the first correction was announced. A subsequent announcement on May 26, 2026, regarding further manufacturing issues triggered an additional 5.07% drop. The law firm Bleichmar Fonti & Auld LLP, which is spearheading the case, has set an August 31, 2026, deadline for investors to petition the court for lead plaintiff status.